Vice President, Research & Design
Over the course of his career, Daniel Keenan has designed, developed, and supported numerous sophisticated technical systems. At AngelMed, Daniel Keenan is currently in charge of all research and development. Research, product development, ongoing engineering, supply chain management, and technical services for clients, partners, and staff members are among his duties. In 2007, Daniel Keenan joined AngelMed.
Daniel formerly served as the Director of Clinical Affairs for AngelMed. Daniel oversaw the 100-site ALERTS Clinical Study while serving in that capacity. He also oversaw AngelMed’s international clinical trial operations in Germany and Brazil. In 2018, the FDA approved the AngelMed Guardian System thanks to the ALERTS Study findings. Daniel Keenan studied computer science at The Catholic University of America before joining AngelMed. After then, he worked for more than ten years as a researcher and developer for IP convergent communications at Bell Laboratories and later Avaya.